FDA approves new drugs

  • On Sept. 2, the U.S. Food and Drug Administration (FDA) approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting. Read more.
  • On Aug. 27, the FDA approved Repatha (evolocumab) injection for some patients who are unable to control their low-density lipoprotein (LDL) cholesterol with current treatment options. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here